Phase I study of XELOXIRI(CPT-11,L-OHP, capecitabine) with Bevacizumab in patients with unresectable advanced/metastatic colorectal cancer

ABSTRACT: Interventions: Patients receive infusional CPT-11,L-OHP, bevacizumab, and oral capecitabine every 21 days. Primary outcome(s): Safety Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2620878 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR